RBB

Julian Gropp

Julian Gropp is an Associate Principal at RBB Economics, based in London. He re-joined RBB in 2021 having spent three years working at another leading economic consultancy in the US.

Julian has extensive experience in the economic assessment of mergers and in the preparation of expert reports and testimony on various competition issues.

Since first joining RBB in 2015, Julian has been involved in numerous high-profile antitrust cases before the UK, the US, and German national authorities and courts as well as the European Commission. He has assisted in preparing expert reports and testimony on a variety of issues arising from antitrust allegations such as abuse of dominance, exclusionary conduct, price fixing, and market allocation.

Julian also has extensive experience analysing the competitive effects of mergers, acquisitions, and JVs, raising horizontal, vertical, and conglomerate concerns.

In addition, Julian has performed and critiqued damage calculations in multiple industrial settings; has experience in class certification issues, including analysing class certification questions in the payments industry; and has advised clients in relation to market inquiries and investigations.

Julian’s experience covers a range of sectors including commodities, health IT, databases, payments, pharmaceuticals, fast-moving consumer goods, rail transport, aircraft components, and industrial products.

Julian holds an MSc in Economics from the University of Warwick. He is fluent in English and German.

Selected Cases

  • Trafigura/ERS

    Merger, EU

  • TRATON/Volvo/Daimler

    JV, EU

  • Oracle/Cerner

    Merger, EU

  • Nordzucker

    Sugar cartel, Germany

  • SAP

    Abuse of dominance, US

  • Mastercard, Visa

    Class certification, US

  • TreeHouse

    Abuse of dominance, US

  • Alstom/Siemens

    Merger, EU

A global network of experienced experts

Our 230-strong, multi-lingual team, spread across 16 offices, has managed over 3,000 cases in 120+ countries, advising on more than one-third of EU Phase II cases in the last 5 years.